Neurocrine Biosciences (NBIX) Stock

CRENESSITY, a new treatment for Classic Congenital Adrenal Hyperplasia (CAH), is now available in the U.S. Patients can get support from CAH-trained pharmacists at PANTHERx Rare, a specialty pharmacy, which operates 24/7. Neurocrine Access Support also offers free information and assistance to patients, caregivers, and healthcare providers.

CRENESSITY is a groundbreaking new treatment for classic congenital adrenal hyperplasia (CAH), marking the first significant advancement in 70 years. Recently approved by the FDA, it is designed to help manage androgens in both adults and children aged four and older with this rare genetic condition. This treatment works by directly lowering excess adrenocorticotropic hormone (ACTH) levels, which can help reduce the need for glucocorticoids.

On Friday, the U.S. Food and Drug Administration announced that it has approved a medication from Neurocrine Biosciences for a specific genetic disorder, according to information on their website.

Neurocrine Biosciences, Inc. saw its share price drop in August due to disappointing phase 2 results for NBI-568 in schizophrenia patients, which makes sense, but the extent of the decline is surprising. The company is valued like a slow-growing big pharmaceutical firm, even though it has strong growth potential. Ingrezza is still generating solid growth and cash flow, and crinecerfont is set to launch in early 2025.

At the 2024 Psych Congress, Neurocrine Biosciences, Inc. shared findings from over 300 patients with tardive dyskinesia who were treated with INGREZZA® (valbenazine) capsules. The results indicated notable enhancements in various aspects of quality of life, including functional, social, emotional, and health-related measures from Phase 3 and 4 studies. Additionally, improvements were observed in patients' independence, emotional well-being, physical health, and adherence to antipsychotic medication in real-world settings.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) held its Q3 2024 Earnings Conference Call on August 30, 2024, at 8:00 AM ET. Key participants included CEO Kyle Gano, CFO Matt Abernethy, and other executives. Various analysts from firms like Goldman Sachs, Stifel, and J.P. Morgan also joined the call to discuss the company's third-quarter results.

While the revenue and earnings per share (EPS) for Neurocrine (NBIX) provide insight into its performance for the quarter ending September 2024, it could be helpful to look at how these important figures stack up against Wall Street predictions and last year's results.

Neurocrine Biosciences (NBIX) reported quarterly earnings of $1.24 per share, which is lower than the Zacks Consensus Estimate of $1.47 per share. This is an increase from earnings of $0.82 per share from the same period last year.

Neurocrine Biosciences, Inc. reported that its third quarter net product sales for INGREZZA® (valbenazine) reached $613 million, showing a 26% increase compared to the previous year. The company has also raised its 2024 sales forecast to between $2.30 and $2.32 billion and announced a $300 million share repurchase plan. CEO Kyle W. expressed confidence in their growth and ability to assist more patients, thanks to their strong financial position and ongoing developments in their neuroscience pipeline.